PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23272911-0	2013	Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment.	Isoflavones	52-63	mechanistic target of rapamycin kinase	Homo sapiens	25-29	
23272911-7	2013	In this review article, we discuss our current understanding of the regulation of PI3K/Akt/mTOR signaling pathways by isoflavones, which could be responsible for their observed in vitro and in vivo activity against human cancers.	Isoflavones	118-129	mechanistic target of rapamycin kinase	Homo sapiens	91-95	
34873494-0	2021	Erratum: A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.	Isoflavones	100-111	mechanistic target of rapamycin kinase	Homo sapiens	147-151	
19472400-0	2009	NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway.	Isoflavones	16-26	mechanistic target of rapamycin kinase	Homo sapiens	94-123	
20177775-0	2010	Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.	Isoflavones	49-60	mechanistic target of rapamycin kinase	Homo sapiens	64-68	
20177775-6	2010	In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells.	Isoflavones	84-95	mechanistic target of rapamycin kinase	Homo sapiens	133-137	
14514441-8	2003	Isoflavone metabolites also exhibited higher antioxidant activity than parent compounds in standard antioxidant (FRAP and TEAC) assays.	Isoflavones	0-10	mechanistic target of rapamycin kinase	Homo sapiens	113-117	
34249417-0	2021	A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.	Isoflavones	91-102	mechanistic target of rapamycin kinase	Homo sapiens	138-142	
29179444-5	2017	Western blot analysis demonstrated that the mammalian target of rapamycin (mTOR) pathway in Y79 cells was inhibited by isoflavones, with a concomitant decrease in cyclin E1, which accounted for the isoflavone-mediated G1 phase arrest.	Isoflavones	119-130	mechanistic target of rapamycin kinase	Homo sapiens	44-73	
29179444-5	2017	Western blot analysis demonstrated that the mammalian target of rapamycin (mTOR) pathway in Y79 cells was inhibited by isoflavones, with a concomitant decrease in cyclin E1, which accounted for the isoflavone-mediated G1 phase arrest.	Isoflavones	119-130	mechanistic target of rapamycin kinase	Homo sapiens	75-79	
29179444-5	2017	Western blot analysis demonstrated that the mammalian target of rapamycin (mTOR) pathway in Y79 cells was inhibited by isoflavones, with a concomitant decrease in cyclin E1, which accounted for the isoflavone-mediated G1 phase arrest.	Isoflavones	119-129	mechanistic target of rapamycin kinase	Homo sapiens	44-73	
29179444-5	2017	Western blot analysis demonstrated that the mammalian target of rapamycin (mTOR) pathway in Y79 cells was inhibited by isoflavones, with a concomitant decrease in cyclin E1, which accounted for the isoflavone-mediated G1 phase arrest.	Isoflavones	119-129	mechanistic target of rapamycin kinase	Homo sapiens	75-79	
29179444-7	2017	Together, these results illustrate that isoflavones inhibit retinoblastoma tumour growth in vitro and vivo and that inactivation of the mTOR pathway and downregulation of cyclin E1 is involved in this action.	Isoflavones	40-51	mechanistic target of rapamycin kinase	Homo sapiens	136-140